The kit, which was launched today, leverages real-time RT-PCR technology to detect and quantify hepatitis C virus-specific RNA with genotypes 1 to 6.
The firm said net product revenues fell 11 percent year over year in the fourth quarter.
The assay is designed to quantitate HBV DNA in serum or plasma to assist in the treatment of chronic HBV-infected patients receiving antiviral therapy.
Developers of POC STI platforms and assays said that the tests provide convenience, privacy, and quick results in an area of testing in need of these benefits.
Qorvo Biotechnologies and Novel Biomarkers Catalyst Lab are developing prototype cartridge-based HCV cAg assays for confirmatory testing.
The company said its molecular collection systems products saw the highest revenue growth during the quarter as product revenues rose 6 percent overall.
The test detects and quantifies hepatitis C virus RNA and can be performed in approximately one hour.
FIND will lead evaluation studies in Cameroon and Georgia between September 2018 and May 2019 to confirm the assay's diagnostic accuracy and commercial utility.
The partners will work together to assess the use of rapid diagnostic tests in decentralized primary healthcare facilities in Malaysia.
The firm's diagnostics division was up 4 percent. Molecular diagnostics grew 7 percent, cytology & perinatal was flat, and blood screening was down 2 percent.